GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (STU:4LN2) » Definitions » Beginning Cash Position

Capricor Therapeutics (STU:4LN2) Beginning Cash Position : €9.63 Mil (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Capricor Therapeutics Beginning Cash Position?

Capricor Therapeutics's Beginning Cash Position for the quarter that ended in Sep. 2024 was €9.63 Mil.

Capricor Therapeutics's quarterly Beginning Cash Position declined from Mar. 2024 (€13.52 Mil) to Jun. 2024 (€5.77 Mil) but then increased from Jun. 2024 (€5.77 Mil) to Sep. 2024 (€9.63 Mil).

Capricor Therapeutics's annual Beginning Cash Position increased from Dec. 2021 (€28.91 Mil) to Dec. 2022 (€32.93 Mil) but then declined from Dec. 2022 (€32.93 Mil) to Dec. 2023 (€8.81 Mil).


Capricor Therapeutics Beginning Cash Position Historical Data

The historical data trend for Capricor Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics Beginning Cash Position Chart

Capricor Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.09 3.21 28.91 32.93 8.81

Capricor Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.22 8.24 13.52 5.77 9.63

Capricor Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


Capricor Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Capricor Therapeutics Business Description

Traded in Other Exchanges
Address
10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

Capricor Therapeutics Headlines

No Headlines